QC
SLXP

QCM Cayman’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

QCM Cayman’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,580
Closed -$578K – 392
2014
Q1 		$578K Buy
+5,580
New +$571K 0.13% 100

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QCM Cayman's SLXP Position: Q2 2014 in Review

QCM Cayman sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014, closing a stake of 5,580 shares — an estimated $578K sold.

QCM Cayman first reported a position in SLXP in Q1 2014 and held it in 1 quarter. The position peaked at $578K in Q1 2014. 308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

  • QCM Cayman reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2014 after selling out during the quarter.
  • QCM Cayman sold 5,580 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2014, an estimated $578K.
  • QCM Cayman first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 1 quarter.
  • QCM Cayman's SALIX PHARMACEUTICALS LTD DEL position peaked at $578K in Q1 2014.
  • 308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on QCM Cayman's 13F filing for Q2 2014, filed 14 Aug 2014.